| 초록 |
Type 2 diabetes mellitus is a disease that increases insulin resistance due to long-lasting hyperglycemia. FGF-21 is a protein mainly expressed in the liver and pancreas, which lowers insulin resistance and reduces plasma levels of glucose. However, since the half-life of FGF21 protein is about 2 hours, the therapeutic effect is limited. Here we designed orally active FGF-21 gene therapy. To this end, we newly prepared chitosan-based gene carrier. The orally administered FGF-21 gene was absorbed into the intestine and circulated through the bloodstream. we confirmed whether FGF-21 polyplex was penetrated through Caco-2 monolayer without cellular toxicity. Next, when FGF-21 polyplex (500 mg) was orally administered, the body weight and blood glucose levels of high-fat diet-induced (HDI) mice were reduced. As on-going works, we are also examining the expression of FGF-21 and changing insulin protein in the pancreas via biopsy of these animals. |
